ArticleBMC rheumatology2025
CMV infection in active systemic lupus erythematosus: clinical characteristics, prognosis and treatment outcomes.
Article in BMC rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case of autoimmune hemolytic anemia with acquired functional mutation of the TLR7.Immunologic research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify factors associated with, and treatment outcomes of Cytomegalovirus (CMV) infection in patients with active systemic lupus erythematosus (SLE).
methodsSLE patients treated with glucocorticoids, with/without immunosuppressive drugs who still had persistently active disease, were identified. All patients who were suspected of having CMV infection and tested for CMV PCR were enrolled. Clinical and laboratory characteristics, SLE disease activity (SLEDAI-2 K) and treatment outcomes were collected. One-year mortality was compared between CMV-infected and non-infected patients.
results103 SLE patients were included. Thirty-seven (35.9%) had CMV infection (DNAemia); CMV disease (group 1) n = 6, symptomatic CMV infection (group 2) n = 8 and CMV infection coexisting with active SLE (group 3) n = 23. Significant characteristics of patients with CMV infection included higher SLEDAI-2 K, proteinuria, lymphopenia, thrombocytopenia, AIHA, alopecia, pleuritis, low C3, higher prednisolone dose, treatment with mycophenolate mofetil and cyclosporine. Multivariable analysis revealed that proteinuria (OR6.95; 95%CI 1.29–37.59; p = 0.024), low C3 (OR5.30; 95%CI 1.09–25.76; p = 0.039) and 30-day-average prednisolone dose > 20 mg/day (OR8.01; 95%CI 1.54–41.63; p = 0.013) were associated with CMV infection. Among non-surviving patients, 8/9(88.9%) had CMV infection. CMV was the direct cause of death in 2 patients and indirect cause in 6 (bacterial sepsis and active disease). Despite ganciclovir treatment, mortality rate was higher in patients in group 1 (66%) compared to group 2 and group 3 (12%). However, fever, leucopenia, nephrotic syndrome, rapidly progressive glomerulonephritis and lung hemorrhage mimic lupus flare, can be reversed after antiviral treatment.
conclusionsDifferent clinical presentations, prognosis and clinical outcomes were identified in SLE patients with CMV infection. After treatment with antiviral therapy, symptomatic CMV infection was associated with the best prognosis. CMV disease was associated with worst prognosis. CMV infection coexisting with active SLE was the most common type of CMV infection in active SLE. This group was associated with variable prognosis according to the clinical context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.